+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Visiongain Publishes Bioprocess Validation Market Report 2021-2031

29 October 2020
Pharma

Visiongain has published a new report on Bioprocess Validation Market Report : Forecasts by Test Type (Extractables and Leachables, Integrity Testing, Microbiology Testing), Process Component (Filter Element, Bioreactors), End User (Biotechnology & Pharmaceutical Companies). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Bioprocess Validationmarket was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.

Validation is a method of building documentary evidence demonstrating a process, activity or procedure, carried out in production or testing maintains the desired level of compliance at all stages. Validation is an action of documenting and demonstrating that any process, procedure, and activity will consistently drive to the required results. It includes the qualifications of equipment and systems.
The global bioprocess validation market is segmented on the basis of process component, test type, end user and geography. The market is segmented into extractable and leachable, integrity testing, microbiology testing. This segment are expected to grow in future.

Market Drivers
High demand for outsourcing of bioprocess validation services, stringent safety and quality regulations governing products certifications and testing beyond the biopharmaceutical and pharmaceutical industries in healthcare industry to maintain the agreement with good manufacturing practices are the important factors propelling the growth of this market.

Competitive Landscape
Global bioprocess validation market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships,acquisitions and others to increase their footprints in this market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. Some companies profiled in the report include- Merck KGaA (Germany) , SGS S.A.(Switzerland),Erofins Scientific(Luxembourg), Sartorius AG (France), Pall Corporation(US), Cobetter FiltrationEquipment co LTD (China),Toxikon corporation (US) , DOC S.R.L (Italy) , Meissner Filtration Products, INC (US), Thermo Fisher Scientific (US)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever